Skip to main content Skip to footer content

The XL CGM System is no longer available

EN: If you have questions, please contact your local Eversense Customer Support team.

DE: Fall Sie Fragen haben, nehmen Sie bitte Kontakt mit Ihrem lokalen Eversense-Kundenbetreuungsteam auf.

ES: Si tiene alguna pregunta, póngase en contacto con su equipo de Servicio de atención al cliente local de Eversense.

FR: Pour toute question, contactez votre équipe locale du support clientèle Eversense.

IT: In caso di domande, si prega di contattare l’Assistenza clienti Eversense locale.

NL: Bij vragen kunt u contact opnemen met uw lokale Eversense-klantenondersteuning.

NO: Hvis du har spørsmål, kan du kontakte det lokale Eversense-kundestøtteteamet ditt.

PL: W razie pytań prosimy o kontakt z lokalnym zespołem obsługi klienta Eversense.

SE: Om du har frågor kan du kontakta din lokala Eversense-kundtjänst.

Disclaimer

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://global.eversensediabetes.com/safety-info.

The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal procedures are performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info.

Senseonics_Logo_White_0